

Catalog# BP-50552

Secukinumab Biosimilar, Human IL17A Monoclonal Antibody

Secukinumab biosimilar uses the same protein sequences as the therapeutic antibody secukinumab. Secukinumab, the humanized anti-IL17A monoclonal antibody, inhibits interleukin 17A, which is a member of the cytokine family, and produced mainly by inflammatory T helper 17 cells. IL17A is upregulated in serum of people with psoriasis and in the synovial fluid of people with psoriatic arthritis, and promotes inflammation when it binds to the interleukin-17 receptor which is expressed in various types of cells, including keratinocytes in skin.

Product Details	
CAS No.	1229022-83-6
Species Reactivity	Human
Source	Mammalian cells
Isotype	Human IgG1 kappa
Class	Monoclonal
Type	Antibody
Clone	Secukinumab Biosimilar
Conjugate	Unconjugated
Immunogen	Human IL17A
Purity	>95%
Molecular Weight	144 kDa
Protein Concentration	1 mg/ml
Formulation	0.2 µM filtered solution, pH 5.8
Storage conditions	4°C for short time, -20°C or -80°C for long time.